"The Untold Story of How High-Quality and Low-Cost Drugs Were Incorporated Into PEPFAR" in the current issue of the Annals

Read More +
  • Networking Event Read more »
  • Read more about the Forum for Collaborative HIV Research Staff Read more »
  • Use of Generic Antiretrovirals for Treatment of HIV in the United States Read more »
  • Response to Global HIV and HCV Epidemics Read more »
  • The Forum's 12th HCV Drug Development Advisory Group (DrAG) Meeting Read more »
  • HCV Drug Development Advisory Group (HCV DrAG): A Video Overview Read more »

Current and Recent Projects

  • July 30, 2014

    Non-alcoholic fatty liver disease (NAFLD), chronic hepatitis B (HBV), and chronic hepatitis C infection are the leading causes of chronic liver disease and hepatocellular carcinoma in the US. NAFLD, comprising non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH) affects 30% of the adult population and at least 10% of children. NASH related liver transplantations are predicted to eclipse other indications over the next decade, and NASH has emerged as the dominant cause of hepatocellular carcinoma (HCC), the only cancer with rising incidence and third leading cause of cancer mortality.

  • July 30, 2014

    Cytomegalovirus (CMV), a common herpes virus that remains latent under normal circumstances, can be reactivated and shed when the immune system is compromised. People who are immune-incompetent or immunocompromised, such as transplant patients, HIV/AIDS patients, and newborn babies, are at risk for severe and life-threatening infections involving fever, pancytopaenia, and inflammatory changes in multiple organs.

  • June 17, 2014

    The Forum HIV Cure Research Project will convene a series of meetings to address the clinical trial and regulatory issues surrounding HIV cure research. Focusing on the ethical, regulatory and clinical factors of HIV cure research, the project will utilize the traditional Forum approach of engaging key stakeholders, including those from the FDA, NIH, academia, advocates, and industry.

 
  • Judith Aberg, MD, Professor of Medicine and Chief, Infectious Diseases, Icahn School of Medicine at Mount Sinai
  • David Anderson, MD, Senior Medical Director, Janssen Services, LLC
  • Cornelius Baker, BA, National Policy Advisor; Senior Communications Advisor, National Black Gay Men's Advocacy Coalition; FHI 360
  • John G. Bartlett, MD, Professor Emeritus, Johns Hopkins University School of Medicine
  • Carol Brosgart, MD, Clinical Professor, University of California, San Francisco
  • Victoria Cargill, MD, MSCE, Director of Minority Research & Clinical Studies, National Institutes of Health
  • Gavin Cloherty, PhD, Associate Director, Global Scientific Affairs, Abbott Molecular
  • Judith Currier, MD, MSc, Professor of Medicine & Division Head of ID, David Geffen School of Medicine, UCLA
  • Victor DeGruttola, ScD, Professor & Chair, Division of Biostatistics, Harvard School of Public Health
  • Carl Dieffenbach, PhD, Director, DAIDS, National Institute of Allergy and Infectious Diseases
  • Stephan Dressler, MD, PhD, EATG Representative, European AIDS Treatment Group
  • David Evans, Director of Research Advocacy, Project Inform
  • Christopher Gordon, PhD, Branch Chief, National Institute of Mental Health
  • Heather Hauck, LICSW, MSW, Director, Division of State HIV/AIDS Programs, Health Resources and Services Administration
  • Sebastien Morin, PhD, Research Office for Industry Liaison Forum International AIDS Society
  • Gabrielle Heilek, PhD, Director, Clinical Research, Roche Molecular Systems
  • Angel Hernandez, ACTG Community Representative, AIDS Clinical Trials Group
  • Sally Hodder, MD, Executive Vice-chair, Department of Medicine; Director of HIV Services, Rutgers New Jersey Medical School, University Hospital
  • King Holmes, MD, PhD, Professor of Medicine/Global Health; Head, Center for AIDS and STD, University of Washington; Harborview Medical Center
  • Michael Horberg, MD, MAS, FACP, Executive Director of Research, Mid-Atlantic Permanente Medical Group, Kaiser Permanente
  • William Hunt, MS, Marketing Director, Celera Corporation
  • Filip Josephson, MD, PhD, Clinical Assessor, Swedish Medical Products Agency; European Medicines Agency
  • Scott Kellerman, MD, MPH, Principal Technical Advisor for HIV Prevention, Management Sciences for Health
  • Michael Lederman, MD, Scott R. Inkley Professor of Medicine, Case Western Reserve University School of Medicine, University Hospital
  • Sandra Nusinoff Lehrman, MD, Global Director, Scientific Affairs - Antivirals, Merck Research Laboratories
  • Christine Lubinski, Vice-President for Global Health, Center for Global Health Policy, Infectious Diseases Society of America
  • Kenneth Mayer, MD, Medical Research Director; Director of HIV Prevention; Visiting Professor of Medicine, The Fenway Institute; Beth Israel Deaconess Medical Center; Harvard Medical School
  • Veronica Miller, PhD, Executive Director, Forum for Collaborative HIV Research
  • Jacques Normand, PhD, Director of AIDS Research, National Institute on Drug Abuse
  • Jean-Michel Pawlotsky, MD, PhD, Professor, Hopital Henri Mondor
  • Dwight Peavy, Executive Director, Newark EMA
  • Chris Petropoulos, PhD, Chief Scientific Officer, Monogram Biosciences
  • Arthur Reingold, MD, Professor and Associate Dean for Research, University of California, Berkeley School of Public Health
  • Boris Renjifo, MD, PhD, Medical Director, Virology, abbVie
  • Brenda Rodriguez, Consultant, Forum for Collaborative HIV Research
  • James Rooney, MD, Vice President of Medical Affairs, Gilead Sciences, Inc.
  • David Ross, MD, PhD, Director, Clinical Public Health Programs, Veterans Health Administration
  • Anna Laura Ross, PhD, Head of International Affairs and Scientific Relations, French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
  • Caroline Ryan, MD, MPH, Chief Technical Officer, US Department of State
  • Jeffrey Schouten, MD, JD, Director, Office of HIV/AIDS Network Coordination
  • Daniel Seekins, MD, Group Medical Director,HIV Medical Strategy, Bristol-Myers Squibb
  • Kimberly Y. Smith, MD, MPH, Vice President, Global Medical Strategy, ViiV Healthcare
  • David Stanton, MN, MPH, Chief, Division of Technical Leadership, US Agency for International Development
  • Kimberly Struble, PharmD, Medical Team Leader, Food and Drug Administration
  • Ronald Valdiserri, MD, MPH, Dep. Assistant Secretary for Health, Infectious Diseases, Department of Health and Human Services
  • Linda Valleroy, PhD, Associate Director for Science, Centers for Disease Control and Prevention
  • Prasad Velisetty, MD, Senior Medical Director, Quintiles Global CRO
  • David Williams, MBA, Principal, MedPharma Partners LLC

The current major pharmaceutical industry sponsors to the Forum Executive Committee are:

abbott_laboratories_logo

abbvie

bms_logo

celera-logo

gilead

janssen_logo

merck_logo

monogram_biosciences_logo

quintiles_logo

roche_logo

viiv_healthcare_logo

Project-specific sponsors are listed on individual project pages